Form 4: Bone Biologics Director Reports New Stock Option Grant and Updated Holdings

Bone Biologics Corp. Director Siddhesh Rajendra Angle reported the grant of new stock options and updated his beneficial ownership of derivative securities in a recent SEC Form 4 filing.

Summary

• Siddhesh Rajendra Angle, a Director and 10% Owner of Bone Biologics Corp. (BBLG), filed a Form 4 statement of changes in beneficial ownership.
• The filing reports a new grant of 62,894 non-employee stock options on June 4, 2025, with an exercise price of $0.88 per share.
• This new option grant was made under the Bone Biologics Corporation 2015 Equity Incentive Plan and vests in four equal quarterly installments.
• The filing also details previously held stock options, including 30,713 shares at an exercise price of $1.73 (granted 9/17/2024 and vesting quarterly), 10,721 shares at $5.12, 154 shares at $387.28, 37 shares at $844.8, 13 shares at $1,260, and 84 shares at $1,260.
• All previously held options, except for the 30,713 options granted on 9/17/2024 and the newly granted 62,894 options, are fully exercisable as of the report date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the grant of new stock options to a director, which aligns interests. However, the presence of significantly out-of-the-money older options introduces a neutral to slightly negative undertone regarding past stock performance.

Positives

• The grant of new stock options to a director aligns their interests with those of shareholders, incentivizing long-term value creation.
• The exercise price of the newly granted options ($0.88) is relatively low, suggesting potential upside for the director if the company's stock price appreciates.

Negatives

• The reporting person holds a significant number of stock options with very high exercise prices ($387.28, $844.8, $1,260), which are substantially higher than the most recent grant's exercise price ($0.88), potentially indicating a significant decline in the company's stock value since those older grants.

Future Outlook

The document is a Form 4 filing, which reports insider transactions and does not typically provide forward-looking statements or guidance on the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transactions, specifically the grant of stock options to a director. Such grants are a common component of executive and director compensation packages across various industries, aiming to align the interests of company leadership with shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• Grant of 62,894 non-employee stock options to Siddhesh Rajendra Angle, a Director and 10% Owner, on June 4, 2025, with an exercise price of $0.88, under the company's 2015 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of the shareholders, potentially incentivizing performance that drives stock value.
• Employees: While this specific filing is for a non-employee director, the mention of the '2015 Equity Incentive Plan' suggests a broader framework for equity compensation that may also benefit employees.

Next Steps

• The 62,894 newly granted stock options will vest in four equal quarterly installments, starting from June 4, 2025.
• The 30,713 stock options granted on September 17, 2024, will continue to vest in four equal quarterly installments.

Key Dates

Keywords

Bone Biologics Corp, BBLG, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Director Compensation, Equity Incentive Plan